Provided by Tiger Fintech (Singapore) Pte. Ltd.

RxSIGHT, INC.

15.04
+0.12000.80%
Post-market: 15.040.00000.00%17:17 EDT
Volume:626.45K
Turnover:9.45M
Market Cap:611.18M
PE:-22.54
High:15.30
Open:15.02
Low:14.72
Close:14.92
Loading ...

Rxsight Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
26 Feb

RxSight Q4 2024 Adj. EPS $0.03 Up From $(0.13) YoY, Sales $40.214M Miss $40.318M Estimate

Benzinga
·
26 Feb

BRIEF-Rxsight Q4 Operating Expenses USD 37.4 Million

Reuters
·
26 Feb

Rxsight Inc: Qtrly Shr Loss $0.15

THOMSON REUTERS
·
26 Feb

Rxsight Q4 Operating Expenses USD 37.4 Million

THOMSON REUTERS
·
26 Feb

Stifel Nicolaus Remains a Hold on RxSight (RXST)

TIPRANKS
·
18 Feb

RxSight, Inc. to Report Fourth Quarter Financial Results on February 25, 2025

GlobeNewswire
·
12 Feb

Insider Stock Buying Reaches US$1.83m On RxSight

Simply Wall St.
·
02 Feb

RxSight price target lowered to $43 from $66 at Needham

TIPRANKS
·
17 Jan

RxSight Price Target Maintained With a $66.00/Share by Needham

Dow Jones
·
13 Jan

Rxsight Inc : Wells Fargo Cuts Target Price to $40 From $42

THOMSON REUTERS
·
13 Jan

RxSight: Balanced Outlook Amid Mixed Q4 Performance and Revised Valuation

TIPRANKS
·
13 Jan

RxSight’s Promising Growth Fueled by Strong Market Performance and Strategic Expansion

TIPRANKS
·
13 Jan

Positive Outlook for RxSight: Strong Revenue and Margin Projections Justify Buy Rating

TIPRANKS
·
13 Jan

RxSight Reports Preliminary Q4 Revenue, Issues 2025 Outlook

MT Newswires Live
·
13 Jan

Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Health Catalyst (HCAT) and Amicus (FOLD)

TIPRANKS
·
13 Jan

RxSight’s Promising Growth and Profitability Prospects Earn a ‘Buy’ Rating

TIPRANKS
·
13 Jan

BTIG Sticks to Its Buy Rating for RxSight (RXST)

TIPRANKS
·
13 Jan

BRIEF-Rxsight Q4 Revenue USD 40.2 Million Vs. IBES Estimate USD 40.4 Million

Reuters
·
12 Jan

Rxsight Outlook FY Revenue USD 185-197 Million

THOMSON REUTERS
·
12 Jan